Table 1.
Clinical data of patients and controls
| Case | Age, years | Gender | PMI, h | pH values | Duration of disease, years | Duration of medication, years | atyptyp | CPE last dose | CPE last 10 years | Cause of death | DSM-IV | Age at onset | Last medication | Cigarettes | Alcohol | Hosp | ECT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SCZ | 64 | F | 11 | 6.7 | 48 | 45 | 3 | 1,536 | 7.7 | pulmonary insufficiency | 295.6 | 16 | clozapine 500 mg, haloperidol 40 mg, ciatyl 40 mg | 0 | no | 21 | yes |
| SCZ | 73 | M | 20 | 6.6 | 43 | 40 | 1 | 507.4 | 1.7 | heart infarction | 295.6 | 30 | perphenazine 32 mg, promethazine 150 mg |
30/day | no | 33 | no |
| SCZ | 43 | M | 18 | 6.9 | 22 | 20 | 2 | 464 | 2.6 | heart infarction | 295.6 | 20 | zuclopethixol 40 mg, valproate 1,200 mg, tiapride 300 mg | 0 | no | 13 | no |
| SCZ | 77 | F | 32 | 6.5 | 49 | 48 | 2 | 2,555 | 8.3 | hmg embolism | 295.6 | 28 | clozapine 400 mg, benperidol 25 mg, chlorprothixen 150 mg | 0 | no | 48 | yes |
| SCZ | 76 | F | 17 | 6.8 | 49 | 47 | 1 | 300 | 4.9 | cardio-pulmonary insufficiency | 295.6 | 27 | perazine 300 mg | 0 | no | 30 | yes |
| SCZ | 63 | F | 31 | 6.8 | 40 | 30 | 3 | 75 | 1.8 | heart infarction | 295.6 | 24 | olanzapine 15 mg | 30/day | no | 30 | yes |
| SCZ | 92 | F | 37 | 6.9 | 51 | 48 | 1 | 100 | 3.4 | cardio-pulmonary insufficiency | 295.6 | 41 | prothipendyl 160 mg, perazine 100 mg | 0 | no | 51 | no |
| SCZ | 71 | M | 28 | 6.4 | 40 | 35 | 1 | 782.4 | 10 | heart infarction | 295.6 | 30 | haloperidol 32 mg, pipamperone 40 mg |
40/day | no | 12 | no |
| SCZ | 51 | M | 7 | 6.1 | 25 | 25 | 1 | 147 | 0.6 | heart infarction | 295.6 | 19 | flupenthixol 15 mg | 30/day | no | 20 | no |
| SCZ | 51 | M | 12 | 6.7 | 28 | 25 | 2 | 450 | 1.,8 | heart infarction | 295.6 | 23 | clozapine 500 mg | 30/day | no | 17 | no |
| SCZ | 81 | M | 4 | 6.7 | 62 | 50 | 1 | 92.8 | 1.4 | heart insufficiency | 295.6 | 19 | haloperidol 40 mg, prothypendyl 80 mg |
20 | no | 48 | no |
| SCZ | 64 | F | 23 | 6.6 | 41 | 40 | 2 | 54.5 | 4.6 | heart infarction | 295.6 | 24 | zotepine 150 mg, olanzapine 10 mg |
20/day | no | 5 | yes |
| Control | 41 | M | 7 | 6.5 | heart infarction | 0 | no | ||||||||||
| Control | 91 | F | 16 | 6.7 | cardio-pulmonary insufficiency | 0 | no | ||||||||||
| Control | 69 | F | 96 | 6.4 | lung embolism | 0 | no | ||||||||||
| Control | 57 | M | 24 | 6.9 | heart infarction | 0 | no | ||||||||||
| Control | 53 | M | 18 | 7 | heart infarction | 0 | no | ||||||||||
| Control | 63 | M | 13 | 6.5 | heart infarction | 0 | no | ||||||||||
| Control | 66 | M | 16 | 6.8 | heart infarction | 0 | no | ||||||||||
| Control | 79 | M | 24 | 6.4 | heart infarction | 0 | no | ||||||||||
atyptyp, duration of atypical treatment/duration of treatment with typical neuroleptics during lifetime; CPE, medication calculated in chlorpromazine equivalents (mg); CPE last 10 years, the sum of medications during the last 10 years in kg; Hosp, hospitalization time in years; ECT, electroconvulsive therapy.